ORPH

AIM-listed Open Orphan plc (LON:ORPH) is lined up for a role in the global fight against coronavirus. Following the acquisition of hVIVO the company is a world leader in the

Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and

Open Orphan plc (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and

On 20 November 2019, the final draft of the ICH Harmonised guideline E9(R1) “Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical

Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and

Open Orphan (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine

How will this impact your development programs from a regulatory perspective. Get updates on the FDA guidance on Demonstrating Substantial Effectiveness and on Adaptive Trial Designs for clinical trials. Venn

Professor John Oxford, consultant to Open Orphan, featured on BBC Radio 2’s Jeremy Vine show discussing the coronavirus outbreak and virology. Jeremy discusses whether the census should be scrapped, using

Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and